Janus Henderson Group PLC Increases Stock Position in Glaukos Corporation $GKOS

Janus Henderson Group PLC lifted its position in shares of Glaukos Corporation (NYSE:GKOS) by 77.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,348,395 shares of the medical instruments supplier’s stock after purchasing an additional 2,329,608 shares during the period. Janus Henderson Group PLC owned 0.09% of Glaukos worth $575,844,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in GKOS. SG Americas Securities LLC increased its stake in Glaukos by 460.8% in the 4th quarter. SG Americas Securities LLC now owns 60,232 shares of the medical instruments supplier’s stock valued at $6,801,000 after buying an additional 49,492 shares during the last quarter. Stephens Inc. AR bought a new position in shares of Glaukos in the first quarter valued at approximately $363,000. Allspring Global Investments Holdings LLC grew its holdings in shares of Glaukos by 32.8% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 355,279 shares of the medical instruments supplier’s stock valued at $39,336,000 after acquiring an additional 87,781 shares in the last quarter. Capricorn Fund Managers Ltd purchased a new stake in shares of Glaukos during the fourth quarter valued at approximately $6,775,000. Finally, DNB Asset Management AS increased its position in shares of Glaukos by 11.9% during the fourth quarter. DNB Asset Management AS now owns 82,320 shares of the medical instruments supplier’s stock valued at $9,295,000 after acquiring an additional 8,770 shares during the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Wells Fargo & Company boosted their price objective on Glaukos from $135.00 to $138.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. Piper Sandler reiterated an “overweight” rating and set a $165.00 target price on shares of Glaukos in a research note on Wednesday, July 1st. Citigroup boosted their price target on shares of Glaukos from $162.00 to $175.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Glaukos in a research report on Friday, July 17th. Finally, Needham & Company LLC raised their price objective on shares of Glaukos from $136.00 to $150.00 and gave the stock a “buy” rating in a report on Wednesday, June 17th. Twelve analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $155.23.

Glaukos Price Performance

Shares of NYSE GKOS opened at $161.97 on Thursday. The company has a current ratio of 5.43, a quick ratio of 4.73 and a debt-to-equity ratio of 0.10. The stock has a fifty day simple moving average of $136.63 and a two-hundred day simple moving average of $124.40. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $166.00. The firm has a market cap of $9.51 billion, a price-to-earnings ratio of -49.38 and a beta of 0.75.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.07. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The firm had revenue of $185.61 million for the quarter, compared to analyst estimates of $150.93 million. During the same period in the previous year, the company posted ($0.24) earnings per share. The business’s revenue was up 49.6% on a year-over-year basis. Analysts anticipate that Glaukos Corporation will post -0.57 earnings per share for the current year.

Key Glaukos News

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Revenue substantially exceeded expectations: Q2 2026 net sales reached a record $185.6 million, up approximately 50% year over year and well above the roughly $151 million analyst consensus. The company’s quarterly loss of $0.14 per share was also narrower than the expected $0.21–$0.28 loss and improved from $0.24 a year earlier. Glaukos Q2 earnings report
• Positive Sentiment: Full-year outlook was raised: Glaukos forecast 2026 revenue of $680 million to $700 million, versus the prior consensus estimate of approximately $630 million. The higher outlook reinforces expectations for continued demand across its glaucoma and other eye-care products. Glaukos second-quarter financial results
• Positive Sentiment: Pipeline progress supports longer-term growth: The pivotal trial of the PRESERFLO MicroShunt for treatment-resistant glaucoma has completed enrollment, an important step toward potential regulatory and commercial expansion. PRESERFLO MicroShunt trial enrollment
• Neutral Sentiment: Analyst sentiment remains broadly favorable, with multiple buy or outperform ratings and recent price targets ranging from $150 to $175. However, UBS initiated coverage with a neutral rating and a $150 target, indicating valuation concerns after the stock’s strong run. UBS Glaukos coverage
• Negative Sentiment: Profitability and cash flow remain weak: Glaukos continues to report an operating and net loss, while operating cash flow was negative during the quarter. Continued investment and losses could limit near-term earnings upside.
• Negative Sentiment: Insider selling may weigh on sentiment: CFO Alex Thurman sold 10,000 shares for approximately $1.6 million. The transaction was made under a pre-arranged Rule 10b5-1 plan, reducing its significance as a discretionary bearish signal, but broader recent insider activity has consisted of sales rather than purchases. Glaukos insider sale

Insider Transactions at Glaukos

In other Glaukos news, COO Joseph E. Gilliam sold 19,573 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $143.54, for a total transaction of $2,809,508.42. Following the sale, the chief operating officer directly owned 73,419 shares of the company’s stock, valued at $10,538,563.26. This represents a 21.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Leana Wen sold 1,700 shares of the stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $143.35, for a total transaction of $243,695.00. Following the transaction, the director owned 19,739 shares of the company’s stock, valued at $2,829,585.65. This represents a 7.93% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 61,273 shares of company stock worth $9,082,003. Insiders own 5.90% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.